Skip to content

Construction of a Self-Management Program for Targeted Therapy-Related Cutaneous Adverse Reactions in Cancer Patients Based on the COM-B Model

Construction of a Self-Management Program for Targeted Therapy-Related Cutaneous Adverse Reactions in Cancer Patients Based on the COM-B Model

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129497
Enrollment
Unknown
Registered
2026-08-05
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental group:Implementing an intervention plan on top of routine care

Sponsors

Dongguan Songshan Lake Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 or older, pathologically confirmed malignant tumor; 2. Currently receiving or about to receive targeted therapy or targeted therapy combined with chemotherapy as an inpatient or outpatient; 3. No previous targeted therapy-related skin adverse reactions; 4. Assessed by a simple mental state exam: illiterate >=17 points, primary school education >=20 points, secondary school or higher >=24 points—considered to have no cognitive impairment, able to learn and take care of themselves, aware of their diagnosis and condition; 5. Voluntarily willing to participate in this study.

Exclusion criteria

Exclusion criteria: 1.Patients with critical illness or in the terminal stage who are unable to participate in the intervention; 2.Patients who have received other related systematic skin care interventions.

Design outcomes

Primary

MeasureTime frame
Enrollment rate;Eligibility rate;Attrition rate;Satisfaction;Adherence;Skin adverse reactions;

Secondary

MeasureTime frame
Self-efficacy;

Countries

China

Contacts

Public ContactJunfeng Zhang

Dongguan Songshan Lake Central Hospital

feng06140119@126.com+86 769 8136 8832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026